Opinion
Video
Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Spotlighting Innovations in Pulmonary Care at ATS 2025
Impedance Cardiography Offers Noninvasive Insight Into PAH Progression